US Pharma MarketingFDA warns telehealth companies over compounded GLP-1s
The FDA has issued a new batch of warning letters to 25 telehealth companies, accusing them of making false and misleading claims in their marketing of compounded GLP-1 weight loss drugs. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and…
The FDA has issued a new batch of warning letters to 25 telehealth companies, accusing them of making false and misleading claims in their marketing of compounded GLP-1 weight loss drugs.
The letters, issued earlier ...
Source: Endpoints News